SSY Group Inkomsten in het verleden

Verleden criteriumcontroles 5/6

SSY Group is de winst gegroeid met een gemiddeld jaarlijks percentage van 9.4%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 5.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 10.5% per jaar. Het rendement op eigen vermogen van SSY Group is 18.2%, en het heeft een nettomarge van 21.1%.

Belangrijke informatie

9.4%

Groei van de winst

9.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	5.6%
Inkomstengroei	10.5%
Rendement op eigen vermogen	18.2%
Nettomarge	21.1%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 31

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Mar 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Mar 28

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

Mar 06

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Feb 13

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

Dec 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Sep 26

SSY Group (HKG:2005) Will Pay A Larger Dividend Than Last Year At HK$0.07

Sep 03

If EPS Growth Is Important To You, SSY Group (HKG:2005) Presents An Opportunity

Aug 31

Estimating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Jun 24

SSY Group (HKG:2005) Will Pay A Larger Dividend Than Last Year At HK$0.08

May 09

Opbrengsten en kosten

Hoe SSY Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SEHK:2005 Opbrengsten, kosten en inkomsten (HKD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	6,469	1,366	1,679	288
31 Mar 24	6,466	1,342	1,760	289
31 Dec 23	6,463	1,319	1,840	290
30 Sep 23	6,413	1,255	1,881	282
30 Jun 23	6,363	1,191	1,921	273
31 Mar 23	6,398	1,157	1,936	266
31 Dec 22	6,434	1,123	1,950	259
30 Sep 22	6,376	1,101	2,020	267
30 Jun 22	6,318	1,080	2,090	274
31 Mar 22	5,838	933	2,040	261
31 Dec 21	5,357	786	1,990	248
30 Sep 21	5,139	713	2,025	212
30 Jun 21	4,921	641	2,060	175
31 Mar 21	4,591	626	1,977	151
31 Dec 20	4,261	612	1,894	127
30 Sep 20	4,177	723	1,766	88
30 Jun 20	4,093	835	1,638	50
31 Mar 20	4,364	985	1,641	25
31 Dec 19	4,636	1,136	1,643	0
30 Sep 19	4,525	1,075	1,628	0
30 Jun 19	4,414	1,014	1,613	0
31 Mar 19	4,297	963	1,590	0
31 Dec 18	4,181	912	1,566	0
30 Sep 18	4,012	867	1,477	0
30 Jun 18	3,844	822	1,387	0
31 Mar 18	3,460	743	1,175	0
31 Dec 17	3,076	665	962	0
30 Sep 17	2,827	616	826	0
30 Jun 17	2,577	567	689	0
31 Mar 17	2,469	528	652	0
31 Dec 16	2,361	490	615	0
30 Sep 16	2,315	426	620	0
30 Jun 16	2,270	363	624	0
31 Mar 16	2,246	383	591	0
31 Dec 15	2,222	403	559	0
30 Sep 15	2,189	443	533	0
30 Jun 15	2,156	482	507	0
31 Mar 15	2,124	487	496	0
31 Dec 14	2,091	492	484	0
30 Jun 14	1,309	402	233	0
31 Mar 14	1,516	386	330	0
31 Dec 13	1,723	369	427	0

Kwaliteitswinsten: 2005 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (21.1%) 2005 } zijn hoger dan vorig jaar (18.7%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van 2005 is de afgelopen 5 jaar met 9.4% per jaar gegroeid.

Versnelling van de groei: De winstgroei van 2005 over het afgelopen jaar ( 14.6% ) overtreft het 5-jarig gemiddelde ( 9.4% per jaar).

Winst versus industrie: De winstgroei 2005 over het afgelopen jaar ( 14.6% ) overtrof de Pharmaceuticals -sector 6.4%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 18.2% ) van 2005 wordt als laag beschouwd.

SSY Group Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023)

SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

First half 2023 earnings released: EPS: HK$0.21 (vs HK$0.19 in 1H 2022)

SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023

Recent updates

SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China

SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China

Investor sentiment improves as stock rises 18%

Chairman & CEO recently bought HK$4.8m worth of stock

Analysts Just Slashed Their SSY Group Limited (HKG:2005) EPS Numbers

SSY Group Limited Announces Update on Product Development

Chairman & CEO recently bought HK$1.5m worth of stock

Consensus EPS estimates fall by 10%

Price target decreased by 10% to HK$5.58

SSY Group Limited Announces Update on Product Development

First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023)

SSY Group's (HKG:2005) Dividend Will Be HK$0.08

First half dividend increased to HK$0.08

SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024

SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited's (HKG:2005) P/E Is On The Mark

Investor sentiment deteriorates as stock falls 16%

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China

Upcoming dividend of HK$0.10 per share

SSY Group (HKG:2005) Is Paying Out A Larger Dividend Than Last Year

SSY Group's (HKG:2005) Upcoming Dividend Will Be Larger Than Last Year's

SSY Group Limited Provides Update on Product Development

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Chairman & CEO recently bought HK$2.5m worth of stock

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

SSY Group Limited, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China

SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market

SSY Group Limited Receives Approval for Gliclazide Tablet

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Ssy Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

SSY Group Limited Provides Update on Product Development

Chairman & CEO recently bought HK$4.7m worth of stock

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045

SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023

SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection

SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China

SSY Group Limited Obtains the Approvals for Drug Production and Registration for Tinidazole Tablets (0.5G) and Ornidazole Tablets (0.5G) from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development